APLS Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
Apellis Pharmaceuticals Inc. Stock Analysis APLS
United States Health Care Mid Cap Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 705 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Read More APLS Chart
Apellis Pharmaceuticals Inc vs S&P 500 Comparative Returns
Analysis of APLS stock performance compared to the broader market (S&P 500) across multiple timeframes.
YTD Performance
- Apellis Pharmac... (APL...) -44.19%
- S&P 500 -4.27%
Apellis Pharmac... Underperformed S&P 500 by 39.92%
1Y Performance
- Apellis Pharmac... (APL...) -57.9%
- S&P 500 8.86%
Apellis Pharmac... Underperformed S&P 500 by 66.76%
3Y Performance
- Apellis Pharmac... (APL...) -51.55%
- S&P 500 37.21%
Apellis Pharmac... Underperformed S&P 500 by 88.76%
5Y Performance
- Apellis Pharmac... (APL...) -43.5%
- S&P 500 92.3%
Apellis Pharmac... Underperformed S&P 500 by 135.80%
Key Statistics
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$17.52Volume
3.00MP/E Ratio (TTM)
-52 Week Range
Market Cap
3.05BAvg. Volume
2.80MDividend Yield
-Financial Metrics & Statements
- Per Share Data
- Ratios
- Statements
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Revenue per Share (TTM) | 3.29 | 0.68 | 0.68 | 3.32 | - |
EBIT per Share (TTM) | -2.81 | -5.5 | -5.37 | -4.33 | - |
Earnings per Share (EPS) (TTM) | - | - | -6.15 | - | - |
EPS Forward | - | -8.84 | -6.15 | -4.45 | - |
Super Investors
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
Joel Greenblatt
% Portfolio:
< 0.01 Recent Activity:100.00%
Jefferies Group
% Portfolio:
0 Recent Activity:-
George Soros
% Portfolio:
0 Recent Activity:-100.00%
Community-Curated Collections ( With APLS )
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Alternate Halal Stocks
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
